Sarepta gains option to Duke's CRISPR tech for DMD

Duke University granted Sarepta Therapeutics Inc. (NASDAQ:SRPT) an option to gain exclusive rights to IP and technology developed in Charles Gersbach's lab to use CRISPR-Cas9 to restore dystrophin expression through the removal of exons. Gersbach is an associate professor of biomedical engineering and director of the Center for Biomolecular and Tissue Engineering at Duke.

Sarepta and Gersbach's lab plan to advance the gene editing platform jointly. Sarepta is to lead clinical development of potential candidates to treat Duchenne muscular dystrophy. Financial terms were undisclosed...